Literature DB >> 15318164

Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF.

M Sedegah1, Y Charoenvit, J Aguiar, J Sacci, R Hedstrom, S Kumar, A Belmonte, D E Lanar, T R Jones, E Abot, P Druilhe, G Corradin, J E Epstein, T L Richie, D J Carucci, S L Hoffman.   

Abstract

One potential benefit of DNA vaccines is the capacity to elicit antibody and T-cell responses against multiple antigens at the same time by mixing plasmids expressing different proteins. A possible negative effect of such mixing is interference among plasmids regarding immunogenicity. In preparation for a clinical trial, we assessed the immunogenicity of GMP-produced plasmids encoding five Plasmodium falciparum proteins, PfCSP, PfSSP2, PfEXP1, PfLSA1, and PfLSA3, given as a mixture, or alone. The mixture induced higher levels of antibodies against whole parasites than did the individual plasmids, but was associated with a decrease in antibodies to individual P. falciparum proteins. T-cell responses were in general decreased by administration of the mixture. Immune responses to individual plasmids and mixtures were generally higher in inbred mice than in outbreds. In inbred BALB/c and C57BL/6 mice, coadministration of a plasmid expressing murine granulocyte-macrophage colony-stimulating factor (mGM-CSF), increased antibody and T-cell responses, but in outbred CD-1 mice, coadministration of mGM-CSF was associated with a decrease in antibody responses. Such variability in data from studies in different strains of mice underscores the importance of genetic background on immune response and carefully considering the goals of any preclinical studies of vaccine mixtures planned for human trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318164     DOI: 10.1038/sj.gene.6364125

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  14 in total

1.  Inclusion of the bovine neutrophil beta-defensin 3 with glycoprotein D of bovine herpesvirus 1 in a DNA vaccine modulates immune responses of mice and cattle.

Authors:  Sarah Mackenzie-Dyck; Jennifer Kovacs-Nolan; Marlene Snider; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

Review 3.  Genetic vaccination approaches against malaria based on the circumsporozoite protein.

Authors:  Sandra Scheiblhofer; Richard Weiss; Josef Thalhamer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

4.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

5.  Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.

Authors:  B Ferraro; K T Talbott; A Balakrishnan; N Cisper; M P Morrow; N A Hutnick; D J Myles; D J Shedlock; N Obeng-Adjei; J Yan; A K K Kayatani; N Richie; W Cabrera; R Shiver; A S Khan; A S Brown; M Yang; U Wille-Reece; A J Birkett; N Y Sardesai; D B Weiner
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

6.  Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.

Authors:  Emily K Forbes; Sumi Biswas; Katharine A Collins; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2011-08-29       Impact factor: 5.422

7.  Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates.

Authors:  Keith Limbach; Joao Aguiar; Kalpana Gowda; Noelle Patterson; Esteban Abot; Martha Sedegah; John Sacci; Thomas Richie
Journal:  Malar J       Date:  2011-03-16       Impact factor: 2.979

8.  Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

Authors:  Cindy Tamminga; Martha Sedegah; David Regis; Ilin Chuang; Judith E Epstein; Michele Spring; Jose Mendoza-Silveiras; Shannon McGrath; Santina Maiolatesi; Sharina Reyes; Victoria Steinbeiss; Charlotte Fedders; Kathryn Smith; Brent House; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna J Banania; Renato Sayo; Fouzia Farooq; Maria Belmonte; Jittawadee Murphy; Jack Komisar; Jackie Williams; Meng Shi; Donald Brambilla; Nalini Manohar; Nancy O Richie; Chloe Wood; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Denise L Doolan; C Richter King; Carter Diggs; Lorraine Soisson; Daniel Carucci; Gail Levine; Sheetij Dutta; Michael R Hollingdale; Christian F Ockenhouse; Thomas L Richie
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

9.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.

Authors:  Walter R Weiss; Anita Kumar; George Jiang; Jackie Williams; Anthony Bostick; Solomon Conteh; David Fryauff; Joao Aguiar; Manmohan Singh; Derek T O'Hagan; Jeffery B Ulmer; Thomas L Richie
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.